BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study. World J Gastroenterol 2007; 13(46): 6231-6235 [PMID: 18069765 DOI: 10.3748/wjg.v13.i46.6231]
URL: https://www.wjgnet.com/1007-9327/full/v13/i46/6231.htm
Number Citing Articles
1
Emmanuel Mitry, Astrid Lièvre, Jean-Baptiste Bachet, Philippe Rougier. Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatmentInternational Journal of Colorectal Disease 2009; 24(6): 605 doi: 10.1007/s00384-009-0672-8
2
Gemma Palazzolo, Hilaria Mollica, Valeria Lusi, Mariangela Rutigliani, Martina Di Francesco, Rui Cruz Pereira, Marco Filauro, Laura Paleari, Andrea DeCensi, Paolo Decuzzi. Modulating the Distant Spreading of Patient-Derived Colorectal Cancer Cells via Aspirin and MetforminTranslational Oncology 2020; 13(4): 100760 doi: 10.1016/j.tranon.2020.100760
3
Osman Köstek, Muhammet Bekir Hacıoğlu, Abdullah Sakin, Tarık Demir, Murat Sarı, Ozlem Ozkul, Murat Araz, Aysun Fatma Doğan, Nazım Can Demircan, Sernaz Uzunoğlu, İrfan Çiçin, Bülent Erdoğan. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?Cancer Chemotherapy and Pharmacology 2019; 83(1): 115 doi: 10.1007/s00280-018-3713-6
4
Hui Wang, Jing Shi, Qin Wang, Hong Li, Kun Cai, Xiaojun Hou, Tao Li, Qi Zhong, Dechao Yu. Assessment of the pre-clinical immunogenicity of a new VEGF receptor Fc-fusion protein FP3 with ELISA and BIACORECancer Immunology, Immunotherapy 2010; 59(2): 239 doi: 10.1007/s00262-009-0744-1
5
Byung Woog Kang, Tae Won Kim, Jae-Lyun Lee, Min-Hee Ryu, Heung Moon Chang, Chang Sik Yu, Jin Cheon Kim, Jong Hoon Kim, Yoon-Koo Kang, Jung Shin Lee. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysisMedical Oncology 2009; 26(1): 32 doi: 10.1007/s12032-008-9077-8